Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ProQR Therapeutics (PRQR) Shares Outstanding (Weighted Average) (2021 - 2025)

Historic Shares Outstanding (Weighted Average) for ProQR Therapeutics (PRQR) over the last 5 years, with Q3 2025 value amounting to $374.1.

  • ProQR Therapeutics' Shares Outstanding (Weighted Average) rose 4810.44% to $374.1 in Q3 2025 from the same period last year, while for Sep 2025 it was $374.1, marking a year-over-year increase of 4810.44%. This contributed to the annual value of $93.2 million for FY2024, which is 632.56% up from last year.
  • According to the latest figures from Q3 2025, ProQR Therapeutics' Shares Outstanding (Weighted Average) is $374.1, which was up 4810.44% from $237.71 recorded in Q2 2025.
  • ProQR Therapeutics' 5-year Shares Outstanding (Weighted Average) high stood at $92.0 million for Q4 2024, and its period low was $97.77 during Q1 2024.
  • In the last 5 years, ProQR Therapeutics' Shares Outstanding (Weighted Average) had a median value of $304.81 in 2023 and averaged $17.1 million.
  • Per our database at Business Quant, ProQR Therapeutics' Shares Outstanding (Weighted Average) plummeted by 5801.33% in 2023 and then skyrocketed by 6979.95% in 2025.
  • Over the past 5 years, ProQR Therapeutics' Shares Outstanding (Weighted Average) (Quarter) stood at $73.4 million in 2021, then decreased by 0.45% to $73.1 million in 2022, then grew by 19.25% to $87.2 million in 2023, then grew by 5.54% to $92.0 million in 2024, then plummeted by 100.0% to $374.1 in 2025.
  • Its last three reported values are $374.1 in Q3 2025, $237.71 for Q2 2025, and $105.19 during Q1 2025.